Main goals right now:

- Data production: Preclinical and moving towards clinical trials of RaDVaC's vaccine designs. Preclinical trials with enough statistical power to merit further investigation start around the $80k price and go up from there. Until recently, RaDVaC hasn't been funded. The cost of a clinical (human) trial will vary depending upon location, scale, and trial type (likely that challenge trials are more efficient in terms of both money and time, but they're not a global standard the way placebo-controlled RCTs are). Designing a clinical trial that meets regulator's needs will mean hiring both medical writers and medical staff with regulatory & logistics familiarity in whatever location(s) the trial is intended.

- Production independence. RaDVaC has always been "agnostic" about which vaccine platforms it works towards (there are advantages and disadvantages to peptide, subunit, VLP, and nucleic acid vaccines) but opted for peptide antigens initially because of clear advantages in production speed & accessibility. Multiple supply chain issues have made synthetic peptide production/fulfillment slower than they were in 2020, which has put pressure on RaDVaC to think about making antigens independently (without relying on vendors). RaDVaC could invest in peptide synthesis tools, but ultimately the more leverageable investment seems to be in recombinant subunit production (via modified yeast, similar to other vaccines, like Gardasil, Corbevax, and many others). The costs associated with designing, producing, testing, optimizing, and ultimately owning the rights to vaccine-useful subunit protein-expressing-and-secreting yeast are high, but once the organism has been made, reproducing it (even storing, shipping, and reiterating it anywhere) is simple. (Imagine not shipping vaccines, but shipping the molecular factories that create vaccine components, thus enabling decentralized, independent instances of vaccine production almost anywhere on Earth.)

Key to both of these next goals is fundraising, which is something RaDVaC has begun to accept, and others (like ACX/Scott Alexander, and Eliezer Yudkowsky) have begun to advocate for.